Fulcrum Therapeutics, Inc.

Dicerna Pharmaceuticals, Inc.

Eli Lilly and Company

Merck Sharp + Dohme Corp.

Flagship Pioneering Innovations Vi, LLC

Hydra Biosciences, Inc.

Qingyi Li

Bertrand Leo Chenard

Chester A Metcalf, Iii

Spencer David Kimball

Ivan Viktorovich Efremov

Peter B Rahl

Owen Brendan Wallace

Lorin A Thompson, Iii

Feng Zhou

Shawn Donald Johnstone

Steven Kazmirski

Blaise S Lippa

Naim Nazef

Xinyuan Edward Wu

David Charles Donnell Butler

Richard A Earl

Dong Zou

Iwona Wrona

Christopher Matthew Liu

Weimin Wang

Andrew J Jackson

Matthew Frank Baevsky

Jared Peters Smit

Neil Kubica

Theonie Anastassiadis

Lily Cheng

Lauren M Chapman

Brett A Cowans

Lisa Mcqueen

Guohua Liang

Richard Alan Earl

Brett Cowans

Chester A Iii Metcalf

Yugui Gu

M Dominic Ryan

The invention relates generally to tRNA-based effector molecules having a non-naturally occurring modification and methods relating thereto.

TREM compositions and uses thereof

The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula I: or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X, X, X, A, A, Y, R, R, R, and Rare as described herein.

Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

Disclosed herein are oligonucleotides, such as nucleic acid inhibitor molecules, having a 4'-phosphate analog and methods of using the same, for example, to modulate the expression of a target gene in a cell. The phosphate analogs are bound to the 4′-carbon of the sugar moiety (e.g., a ribose or deoxyribose or analog thereof) of the 5′-terminal nucleotide of an oligonucleotide. Typically, the phosphate analog is an oxymethylphosphonate, where the oxygen atom of the oxymethyl group is bound to the 4′-carbon of the sugar moiety or analog thereof.

4'-phosphate analogs and oligonucleotides comprising the same

Disclosed herein are oligonucleotides, such as nucleic acid inhibitor molecules, having a 4'-phosphate analog and methods of using the same, for example, to modulate the expression of a target gene in a cell. The oligonucleotide of the disclosure comprises a 5&#x2032;-terminal nucleotide represented by Formula III: wherein R, R, B, Xand Y are as defined in the specification. The phosphate analogs are bound to the 4&#x2032;-carbon of the sugar moiety (e.g., a ribose or deoxyribose or analog thereof) of the 5&#x2032;-terminal nucleotide of an oligonucleotide. Typically, the phosphate analog is an oxymethylphosphonate, where the oxygen atom of the oxymethyl group is bound to the 4&#x2032;-carbon of the sugar moiety or analog thereof. An illustrative 5&#x2032;-terminal nucleotide of an oligonucleotide of the disclosure may have the following chemical structure: 

The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).

Inhibiting the transient receptor potential A1 ion channel

This disclosure describes novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain and respiratory conditions.

Growing community of inventors

Somerville, MA, United States of America

Qingyi Li